Skip to main content
Print Save

Measles Virus Vaccine / Mumps Virus Vaccine / Rubella Virus Vaccine / Varicella Virus Vaccine Dosage

Medically reviewed by Drugs.com. Last updated on Aug 7, 2023.

Usual Pediatric Dose for:

Additional dosage information:

Usual Pediatric Dose for Varicella-Zoster - Prophylaxis

1 dose (0.5 mL) subcutaneously in the outer deltoid or higher anterolateral thigh

Comments:

  • The first dose is usually administered at 12 to 15 months of age.
  • A second dose, if needed, is usually administered at 4 to 6 years of age.

Use: Active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age.

Usual Pediatric Dose for Vaccination

1 dose (0.5 mL) subcutaneously in the outer deltoid or higher anterolateral thigh

Comments:

  • The first dose is usually administered at 12 to 15 months of age.
  • A second dose, if needed, is usually administered at 4 to 6 years of age.

Use: Active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age.

Usual Pediatric Dose for Mumps Prophylaxis

1 dose (0.5 mL) subcutaneously in the outer deltoid or higher anterolateral thigh

Comments:

  • The first dose is usually administered at 12 to 15 months of age.
  • A second dose, if needed, is usually administered at 4 to 6 years of age.

Use: Active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age.

Usual Pediatric Dose for Rubella Prophylaxis

1 dose (0.5 mL) subcutaneously in the outer deltoid or higher anterolateral thigh

Comments:

  • The first dose is usually administered at 12 to 15 months of age.
  • A second dose, if needed, is usually administered at 4 to 6 years of age.

Use: Active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age.

Usual Pediatric Dose for Measles Prophylaxis

1 dose (0.5 mL) subcutaneously in the outer deltoid or higher anterolateral thigh

Comments:

  • The first dose is usually administered at 12 to 15 months of age.
  • A second dose, if needed, is usually administered at 4 to 6 years of age.

Use: Active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

  • Anaphylactic reaction to neomycin; if vaccination is medically necessary, consult an allergist or immunologist and administer only where anaphylactic reactions can be appropriately managed.
  • Hypersensitivity to any of the ingredients, gelatin, or other measles-, mumps-, or rubella-containing vaccine.
  • Immunosuppression: do not administer to patients with blood dyscrasias, leukemia, any type of lymphoma or other malignant neoplasm affecting the bone or lymph system, and patients on immunosuppressive therapy including high dose systemic corticosteroids; live, attenuated vaccines like varicella can cause more extensive rash or disseminated disease in immunosuppressed individuals.
  • This vaccine may be used in patients on topical or low-dose corticosteroids such as those commonly used for asthma or prophylaxis therapy (e.g. for Addison's disease).
  • Primary or acquired immunodeficiency including AIDS or manifestations of human immunodeficiency virus infection, cellular immune deficiencies, and hypogammaglobulinemia and dysgammaglobulinemia; measles including body encephalitis, pneumonitis, and death because of disseminated measles vaccine virus infection have occurred in severely immunocompromised individuals and immunodeficient children inadvertently given measles-contain vaccine.
  • Family history of congenital or hereditary immunodeficiency unless immune competence is demonstrated.
  • Active untreated tuberculosis or active febrile illness with fever over 101.3F
  • Pregnancy: fetal effects are unknown. Pregnancy should be avoided for 3 months following vaccination.

Safety and efficacy have not been established in patients younger than 12 months or older than 12 years.

To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS) at: https://vaers.hhs.gov

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer